| 发明名称 | Method of reducing intraocular pressure in humans | ||
| 摘要 | Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | ||
| 申请公布号 | US9289383(B2) | 申请公布日期 | 2016.03.22 |
| 申请号 | US201414552160 | 申请日期 | 2014.11.24 |
| 申请人 | Inotek Pharmaceuticals Corporation | 发明人 | Kim Norman N.;McVicar William K.;McCauley Thomas G.;Jagtap Prakash |
| 分类号 | A61K31/70;A61K9/00;A61K31/495;A61K31/7076;C07H19/167;A61K45/06;C07H19/16 | 主分类号 | A61K31/70 |
| 代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;Kanik Cynthia L. |
| 主权项 | 1. A method of reducing intraocular pressure comprising the step of: delivering an effective amount of cyclopentyladenosine (CPA) according to Formula I, or a pharmaceutically acceptable salt thereof, to the anterior chamber of an affected eye of a humanwith the proviso that the compound of Formula I is not delivered in the form of compound A | ||
| 地址 | Lexington MA US | ||